



Immunomodulatory role of Interleukin-33 in large vessel vasculitis

Anne Claire Desbois, Patrice Cacoub, Aurelie S Leroyer, Edwige Tellier, Marlene Garrido, Anna Maciejewski-Duval, Cloe Comarmond, Stéphane Barete, Michel Arock, Patrick Bruneval, et al.

► To cite this version:

Anne Claire Desbois, Patrice Cacoub, Aurelie S Leroyer, Edwige Tellier, Marlene Garrido, et al.. Immunomodulatory role of Interleukin-33 in large vessel vasculitis. *Arthritis & rheumatology*, 2017. hal-01791559

HAL Id: hal-01791559

<https://amu.hal.science/hal-01791559>

Submitted on 7 Feb 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

OPEN

Immunomodulatory role of Interleukin-33 in large vessel vasculitis

Anne-Claire Desbois^{1,2,3,4}, Patrice Cacoub^{1,2,3,4}, Aurélie S. Leroyer⁵, Edwige Tellier⁵, Marlène Garrido^{1,2}, Anna Maciejewski-Duval^{1,2}, Cloé Comarmond^{1,2,3,4}, Stéphane Barete^{3,4}, Michel Arock^{6,7}, Patrick Bruneval⁸, Jean-Marie Launay⁹, Pierre Fouret¹⁰, Ulrich Blank¹¹, Michelle Rosenzweig^{1,2,3,4}, David Klatzmann^{1,2,3,4}, Mohamed Jarraya¹², Philippe Cluzel¹³, Fabien Koskas¹⁴, Gilles Kaplanski^{3,15} & David Saadoun^{1,2,3,4*}

The mechanisms regulating inflammation in large vessels vasculitis (LVV) are poorly understood. Interleukin 33 (IL-33) has been shown to license innate and adaptive immunity by enhancing Th2 cytokines production. We aimed to examine the role of IL-33 in the immunomodulation of T cell activation in LVV. T cell homeostasis and cytokines production were determined in peripheral blood from 52 patients with giant cell arteritis (GCA) and 50 healthy donors (HD), using Luminex assay, flow cytometry, quantitative RT-PCR and by immunofluorescence analysis in inflammatory aorta lesions. We found increased level of IL-33 and its receptor ST2/IL-1R4 in the serum of patient with LVV. Endothelial cells were the main source of IL-33, whereas Th2 cells, Tregs and mast cells (MC) express ST2 in LVV vessels. IL-33 had a direct immunomodulatory impact by increasing Th2 and Tregs. IL-33 and MC further enhanced Th2 and regulatory responses by inducing a 6.1 fold increased proportion of Tregs ($p = 0.008$). Stimulation of MC by IL-33 increased indoleamine 2,3-dioxygenase (IDO) activity and IL-2 secretion. IL-33 mRNA expression was significantly correlated with the expression of IL-10 and TGF- β within aorta inflammatory lesions. To conclude, our findings suggest that IL-33 may exert a critical immunoregulatory role in promoting Tregs and Th2 cells in LVV.

Large vessel vasculitis (LVV) mainly include giant cell arteritis (GCA). LVV may lead to segmental stenosis, occlusion, dilatation and/or aneurysm formation in the aorta and/or its main branches¹. Histological lesions are characterized by an inflammatory infiltrate located in the inner part of aortic wall (*media*) associated with a fragmentation of the internal elastic lamina and hyperplasia of *vaso vasori*. LVV are driven by common immune mechanisms in the activation and regulation of CD4 T cells. Indeed, vascular lesion formation is mediated by inadequate immune response, characterized by *in situ* activation of CD4 T cells. Weyand *et al.*, have shown the deficiency of the programmed cell death protein-1 immune checkpoint in GCA promoting CD4+ T cells activation¹. Apart from the strength of the antigen/T-cell receptor (TCR) signal, the microenvironment is also critical in T-cell activation and polarisation. Previous studies have provided evidence that LVV inflammation was driven

¹Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology- Immunotherapy (I3), F-75005, Paris, France. ²Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Hôpital Pitié-Salpêtrière, AP-HP, F-75651, Paris, France. ³AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France. ⁴Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, Paris, France. ⁵Aix-Marseille Univ; INSERM, Vascular Research Center of Marseille, UMR-S 1076, 13385, Marseille, France. ⁶Laboratoire de biotechnologies et pharmacologie génétique appliquée, CNRS UMR 8147, ENS - Ecole normale supérieure de Cachan, Cachan, France. ⁷AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire d'Hématologie Biologique, Paris, France. ⁸Laboratoire d'anatomopathologie, Hôpital Européen Georges Pompidou, Paris, France. ⁹INSERM, UMR-S 942, F-75010, Paris, France. ¹⁰Laboratoire d'anatomopathologie; Groupe Hospitalier Pitié-Salpêtrière, Paris, France. ¹¹Inserm U1149, CNRS ERL8252, Faculté de Médecine Site X. Bichat, Paris, France. ¹²Banque des tissus Humains, Hôpital saint Louis, Paris, France. ¹³Service de radiologie vasculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. ¹⁴Service de Chirurgie vasculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. ¹⁵APHM, CHU Conception, Service de Médecine Interne, Marseille, France. *email: david.saadoun@aphp.fr

Parameters	GCA n=52
Demographic features	
Median age [IQR]	74.7 [66.3; 83.2]
Female gender	35 (67.3%)
Geographic origin	
Caucasian	50 (96.2%)
African	0 (0%)
North African	2 (3.8%)
Other	0 (0%)
Clinical features	
Stroke	7 (13.4%)
Aortic aneurysms	4 (7.7%)
Aortitis	14 (26.9%)
Ocular complications	5 (9.6%)

Table 1. Main demographical and clinical characteristics of LVV patients.

by Th1 and Th17 cells in the peripheral blood and inflamed tissues^{2–4}. They also demonstrated a quantitative deficiency of regulatory T cells (Tregs)⁵. However, the mechanisms involved in regulation of CD4 T cell homeostasis in LVV are poorly understood and need to be further studied in order to highlight potential therapeutic targets.

Ciccia *et al.* have reported overexpression of IL-33 within inflammatory lesions of temporal arteries in GCA patients⁶. A meta-analysis has found an association of GCA and an IL-33 genetic variant⁷. Interleukin 33 (IL-33), a recently identified cytokine belonging to the IL-1 family⁸, is known to be implicated in the regulation of immune response in several human diseases^{9–12}. IL-33 is constitutively expressed in the nucleus of epithelial, endothelial cells and also fibroblasts and has been shown to license innate and adaptive immunity by enhancing Th2 cytokines production. IL-33 is secreted secondary to cell apoptosis and necrosis. IL-33 binds to a heterodimeric receptor called ST2/IL-1R4, expressed mainly on Th2 cells, Tregs, mast cells, eosinophils, basophils, Group 2 Innate Lymphoid Cells (ILC2s) and Natural Killer (NK) cells¹³. During inflammation, several mechanisms allow the regulation of IL-33 effects, such as sST2, a soluble form of ST2 acting as a decoy receptor that inhibits IL-33 signalling. Studies have demonstrated that IL-33 is a key regulator of the immune response, and is involved in many autoimmune and inflammatory disorders. However, its immune function in patients with LVV is largely unknown.

The present study examined the critical role of IL-33 to modulate T cell activation in LVV.

Methods

Patients. The study population consisted of 52 GCA patients (median [IQR] age at diagnosis: 74.7 [66.3; 83.2] years), fulfilling the international criteria for GCA, respectively^{14,15}. Clinical characteristics of LVV patients are indicated in Table 1. For IL-33 measurement in sera, 50% and 24.5% of samples were performed in patients with active disease and without treatment, respectively. For functional experiments, PBMC and CD4+ T cells were obtained from patients who were untreated or receiving corticosteroids <10 mg/day. Blood samples from 50 age and sex-matched healthy donors (HD) were obtained from Etablissement Français du Sang (Hôpital Pitié-Salpêtrière) and were used as controls. Aorta biopsies were obtained from consecutive GCA patients undergoing surgical repair for aortic aneurysm or dissection. Three non-inflammatory aorta biopsies were provided by a tissue bank and obtained from vessels taken for transplant in multi-organ and tissue donors. Temporal arteries and aorta were obtained at diagnosis and some aortas specimens were collected during a vascular complication.

The study was approved by our institutional ethics review board (*Comité de Protection des Personnes-Ile-de-France-VI*) and was performed according to the Helsinki declaration. Donors gave informed consent.

Analysis of cytokine production. Levels of IL-33 *in sera* were performed using enzyme-linked immunosorbent assay (ELISA, R&D systems) in LVV patients and HD. ST2 level *in sera* was performed using enzyme-linked immunosorbent assay (ELISA, R&D systems) in GCA patients and HD. Quantitative determination of Th1 (IFN γ), Th17 (IL-17), Th2 (IL-4, IL-5, IL-13) cytokines, IL-10 and IL-6, was performed in culture supernatant using Human Cytokine 25-Plex (Invitrogen, France) in accordance with the manufacturer protocol.

For intracellular staining, peripheral blood mononuclear cells (PBMCs) were stimulated for 4 hours with 0,05 μ g/mL Phorbol 12-myristate 13-acetate (PMA) and 1 mM (1 μ g/mL) ionomycin (Sigma-Aldrich) in the presence of brefeldin A (BD Pharmingen) and were stained with the following conjugated monoclonal antibodies, at predetermined optimal dilutions, for 15 minutes at room temperature: CD3-APC-Alexa Fluor 750, CD4-ECD, CD8-APC-Alexa Fluor 700, (Beckman Coulter). Intracellular detection of IL-4-PE (BD, France), IFN γ -FITC (Miltenyi Biotec), TNF α -PE (Miltenyi Biotec), IL17-eFluor 660 (ebioscience), IL-10-APC (BD, France) was performed on fixed and permeabilized cells using appropriate buffer (BD Pharmingen).

For analysis of regulatory T cells (Tregs), intranuclear detection of FOXP3-AF647 (Beckman Coulter), with CD3-FITC (Beckman Coulter), CD8-KO (Beckman Coulter), CD4-PB (Beckman Coulter), CD127-PC7 (Beckman Coulter), CD25-PE (BD) was performed using PerFIX-nc Kit (Beckman Coulter). Data were acquired using a Navios flow cytometer and analyzed with the Kaluza analysis software (Beckman Coulter).

For all analyses, the gating strategy consisted in excluding debris and dead cells, then selecting CD3+ T cells among lymphocytes, and thereafter studying markers of interest among those CD3+ CD4+ T cells.

T cell differentiation with IL-33. Peripheral blood mononuclear cells (PBMCs) of LVV patients were cultured in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS) and 2% penicillin-streptomycin (1×10^6 cells/ml) and stimulated in 48-well plates coated with anti-CD3/CD28 monoclonal antibodies with or without 10 ng/mL human recombinant IL-33 (eBiosciences). After 3 and 5 days of culture, culture supernatants were harvested and immediately frozen. Quantitative determination of IL-4, IL-10, IL-5, IL-13 and IFN γ , IL17 in culture supernatant was performed using Human Milliplex[®] kit (Merck Millipore, France) in accordance with the manufacturer protocol. Intracellular expression of Th1 and Th2 cytokines was determined by flow cytometry (Navios, Beckman Coulter). The proportion of CD4+ CD25High CD127Low FOXP3+ cells among TCD4+ cells was assessed by flow cytometry.

In order to investigate the impact of mast cells on Tregs in presence of IL-33, CD4+ T cells (1×10^6) of LVV patients were purified from PBMC according the instructions of the manufacturer (Stemcell[®]) and were co-cultured in 24-well plates coated with anti-CD3/CD28 monoclonal antibodies for 4 days with or without human ROSA^{KITWT} mast cells (2.5×10^5) in the presence or the absence of recombinant IL-33. The proportion of FOXP3+ CD25High CD4+ cells in each condition was assessed by flow cytometry as described previously.

Assessment of indoleamine-2, 3-deoxygenase (IDO) activity. The kynurenin to tryptophan ratio was used as a surrogate indicator of IDO activity. Levels of tryptophan and kynurenin were analyzed by isocratic liquid chromatography with coulometric detection¹⁷.

Immunofluorescence analysis. Detection of IL-33⁺, Von Willebrand Factor, ST2/IL-1R4⁺, CD3⁺, FOXP3⁺, Tryptase⁺, IL-10⁺, VEGF (Vascular Endothelial Growth Factor) and IL-4⁺ cells was performed on fixed, paraffin-embedded samples from 5 consecutive temporal arteries and 13 consecutive aorta of GCA patients with active inflammatory arterial lesions and 5 temporal arteries of controls and 3 non-inflammatory aorta. After dewaxing in baths of xylene and ethanol, slides were submitted to antigen retrieval by heating in citrate buffer pH 6.0. Before incubation with primary antibodies, Fc receptor was blocked with normal goat serum 5%. Slides were incubated over night with monoclonal mouse anti-human CD3 (dilution 1:50, Abcam) rabbit polyclonal anti Von Willebrand Factor (dilution 1:250, Dako Cytomation), mouse monoclonal anti-IL-33 (dilution 1:1000, Enzo Life Sciences), rabbit polyclonal anti-ST2 (dilution 1:100, Sigma-Aldrich), rabbit polyclonal anti-IL-4 (dilution 1:50, Abcam), rabbit polyclonal anti IL-10 (dilution 1:25, Abcam), rat monoclonal anti-FoxP3 (1:100, eBioscience), mouse anti-tryptase (1:400, DAKO) or with isotype control: polyclonal Rabbit IgG or monoclonal mouse IgG (Abcam) or monoclonal rat IgG (eBioscience). Slides were then incubated for 2 hours at room temperature with Cy3-conjugated goat anti-mouse (working dilution 1:1000, Jackson ImmunoResearch) and Alexa 488 donkey anti-rabbit (working dilution 1:1000, Life Technologies), mounted in Mowiol, and evaluated under fluorescence microscopy.

Gene expression quantification at the mRNA level in aortic tissues. Quantification of mRNA expression was performed on paraffin-embedded aorta samples from GCA (n = 20) patients and non-inflammatory aorta controls (n = 3). ST2, IL-1 β , IL-10, TNF α , IL-6, IL-8, IFN γ , IL-4, GATA-3, FOX-P3, T-BET, ROR- γ t, CD-45 genes were analyzed. The theoretical and practical aspects of real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) using the ABI Prism 7900 Sequence Detection System (PerkinElmer Applied Biosystems, Foster City, CA) have been described in detail elsewhere (13). Briefly, total FFPE RNA was extracted using the High Pure FFPE RNA Isolation Kit (Roche) following the supplier's protocol and reverse transcribed before real-time PCR amplification. Gene mRNA expression levels were quantified by using real time RT-PCR. Quantitative values were obtained from the cycle number (C_t value) at which the increase in the fluorescence signal associated with exponential growth of PCR products started to be detected by the laser detector of the ABI Prism 7900 Sequence Detection System (Perkin-Elmer Applied Biosystems), using PE Biosystems analysis software according to the manufacturer's manuals. The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e., lack of extensive degradation) are both difficult to assess. We therefore also quantified transcripts of the *RPLP0* gene (Genbank accession: NM_001002) encoding the ribosomal protein subunit P0 as an endogenous RNA control and normalized each sample on the basis of its *RPLP0* content. Results, expressed as N -fold differences in target gene expression relative to the *RPLP0* gene and termed " N_{target} " were determined as $N_{\text{target}} = 2^{\Delta C_t \text{-sample}}$, where the ΔC_t value of the sample was determined by subtracting the average C_t value of the target gene from the average C_t value of the *RPLP0* gene. The N_{target} values of the samples were subsequently normalized to obtain a 'basal mRNA level' (smallest amount of mRNA quantifiable ($C_t=35$)) equal to 1. The primers for all genes were chosen with the assistance of the Oligo 6.0 program (National Biosciences). We scanned the dbEST and nr databases to confirm the total gene specificity of the nucleotide sequences chosen for the primers and the absence of SNPs. To avoid amplification of contaminating gDNA, 1 of the 2 primers was placed at the junction between 2 exons or on 2 different exons. Agarose gel electrophoresis was used to verify the specificity of PCR amplicons.

Culture of temporal arteries. Temporal arteries of GCA patients (n = 8) and controls (n = 5) were cultured for 24 hours without or with 10 ng/ml recombinant human IL-33 for 24 hours. Temporal arteries were then incubated for 24 h in RNAlater at +4°C and then frozen at -80°C. Culture supernatants were collected and immediately frozen at -80°C. The determination of cytokines dosages in supernatants was performed using Milliplex[®] kit (Merck Millipore, France) in accordance with the manufacturer protocol. Quantification of IL-1 β , IL-10, TNF α , IL-6, IL-8, IFN γ , IL-4, CD-45 mRNA was also performed. Temporal arteries were lysed and homogenized. Total RNA was extracted by TRIzol reagent (Invitrogen) and reverse-transcribed using SuperScript VILO

cDNA Synthesis Kit (Invitrogen) both according to the manufacturer's instruction. Gene expression was determined by real-time PCR. Each cDNA sample was amplified in triplicate using SYBR Green (Applied Biosystems) on 7500 FAST Real-time PCR System (Applied Biosystems). The thermal cycling conditions comprised an initial denaturation step at 95 °C for 10 minutes, followed by 40 cycles at 95 °C for 15 seconds and 65 °C for 1 minute. Quantitative values were obtained from the threshold cycle (Ct) number at which the increase in the signal associated with exponential growth of PCR products began to be detected. *GADPH* gene was used as an endogenous control and each sample was normalized on the basis of its *GADPH* content and the expression of CD45. The primers were designed to span introns and are listed in supplementary Table.

Statistics. Continuous variables are presented with the median and range or with the mean \pm SEM. Categorical variables are presented with counts and proportions. Statistical comparisons were performed by using the Mann-Whitney test for quantitative unpaired data, and the Wilcoxon matched pairs test for quantitative paired data. All statistical tests were two-tailed with a significance level of 0.05. Statistical significance was evaluated using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA).

Results

Expression of Th2 and regulatory cytokines in blood and inflamed vessels in LVV. IL-33 is known to be implicated in the regulation of immune response by enhancing Th2 cytokines production and Tregs. To study the effects of IL-33 on CD4⁺ T cells homeostasis in LVV, we first evaluated if Th2 and regulatory responses were present in blood and inflamed vessels in LVV patients besides the secretion of Th1 and Th17 cytokines, previously shown in LVV (Fig. S1).

We first evaluated the level of Th2 and regulatory (IL-10) cytokines in culture supernatant of PBMC after 4 hours of PMA-ionomycin stimulation. Comparisons of cytokines between LVV patients and HD are presented in Fig. 1A–C. Active LVV patients had significantly increased median levels of IL-4 ($p = 0.01$), IL-5 ($p = 0.002$) and IL-10 ($p = 0.003$) as compared to HD. Consistently, the quantitative analysis of mRNA within inflammatory lesions of LVV aorta revealed an overexpression of GATA 3 (11 ± 17), as compared to controls with non-inflammatory aorta aneurysms ($p = 0.006$) (Supplementary Data S2). Immunofluorescence analyses of aorta tissue specimens from patients with LVV also revealed an expression of IL-4 and IL-10, partially by T cells (Figs. 1D and S3). Within inflammatory lesions, immunofluorescence analysis of aorta in patients with LVV also revealed that Tregs (defined as positive FOXP3 cells) expressed ST2/IL-1R4 (Figs. 1D and S3). Consistently, the quantitative analysis of mRNA within inflammatory lesions of LVV aorta revealed an overexpression of FOXP3 (44.2 ± 55.2 , $p = 0.005$), as compared to controls with non-inflammatory aorta aneurysms (**data not shown**).

We next assessed in LVV patients the expression of IL-33 and other cytokines known to promote Th2 polarisation (i.e. IL-25 and TSLP (Thymic stromal lymphopoietin)). We found overexpression of IL-33 in LVV relative to HD (Fig. 1E). A significant increased level of IL-33 was observed in sera of LVV patients as compared to HD ($449.4 (\pm 894.9)$ vs $67.7 (\pm 204.6)$ pg/mL, $p = 0.002$) (Fig. 1E). Consistently, mean level of IL-33 receptor (soluble ST2) was increased in sera of LVV patients as compared to HD ($n = 17$) [$2808.7 (\pm 1284.7)$ and $677.7 (\pm 322)$ in HD, $p < 0.0001$] (Fig. 1F). In contrast, levels of IL-25 and of TSLP were not different in LVV and in HD (Fig. 1G,H).

IL-33 and its receptor ST2 are overexpressed in pathological vessels of LVV patients. We next studied the expression of IL-33 in LVV inflammatory vessels and controls. Immunofluorescence analyses of temporal arteries and aorta tissue specimens from LVV patients and controls were used to investigate the expression pattern of IL-33 and ST2/IL-1R4. IL-33 was mainly expressed within adventitial vessels in co-localization with endothelial cells [i.e. von willebrand factor (WF)] and in a lesser extent within few inflammatory cells in aorta (Fig. 2A) and temporal arteries. Expression of ST2/IL-1R4 was observed within the inflammatory infiltrates of aorta (Fig. 2B) and temporal arteries of LVV patients. The proportion of IL-33 positive vessels was higher in aorta of LVV ($n = 5$) patients as compared to controls ($p = 0.036$) (Fig. 2C).

IL-33 predominantly induces a Th2 and regulatory immune responses in LVV. Through ST2 binding, IL-33 is known to be able to induce helper T cells, mast cells and eosinophils to produce type 2 cytokines in allergy. We next attempted to determine whether IL-33 overexpression was accompanied by an increase in Th2 cytokines in LVV. Freshly isolated PBMC from LVV patients (with corticosteroids < 15 mg/day) and controls were cultured with anti-CD3/CD28 with or without IL-33 stimulation for 5 days. The secretion of cytokines was evaluated by flow cytometry (Figs. 3A, S4) and by quantitative determination in culture supernatants (Fig. 3B) after 5 days of PBMC culture with anti-CD3/CD28 monoclonal antibodies.

The proportion of CD4⁺ cells secreting IL-4 was increased after IL-33 stimulation [$9.6 (\pm 11.7)$ % vs $7.06 (\pm 9.1)$ %, $p = 0.006$] in LVV patients but not in HD (Fig. 3A). IL-33 stimulation led to an increase of IL-5, IL-4 and IL-13 production in culture supernatants of PBMC after 5 days of culture with anti-CD3/CD28 monoclonal antibodies [$332.7 (\pm 237.2)$ pg/ml with IL-33 vs. $200.1 (\pm 176.1)$ pg/ml without IL-33, $p = 0.005$ and $18.1 (\pm 15.4)$ pg/ml with IL-33 vs $13.9 (\pm 11.4)$ pg/ml without IL-33, $p = 0.02$ and $1479.5.6 (\pm 669.9)$ pg/ml with IL-33 vs $1317.6 (\pm 644.9)$ pg/ml without IL-33, $p = 0.07$, respectively], but not of IFN $_{\gamma}$, IL-17 and IL-10 (Fig. 3A,B).

Since regulatory T cells (Treg) can also express ST2/IL-1R4, we next studied the impact of IL-33 on the proportion of Tregs. We have shown that IL-33 induced an increased proportion of Tregs after 5 days of PBMC culture [5.3% without IL-33 vs 6.2% with IL-33, ($p = 0.001$)] (Figs. 3C, S5). In addition, Tregs expanded by IL-33 were functional (i.e. assessed by their ability to inhibit effector T cells proliferation, Fig. S6).

We next studied the correlation between Th2 and regulatory cytokines and IL-33 expression in LVV arteries in order to study the *in vivo* effects of IL-33. We assessed by quantitative PCR (qPCR) the expression of IL-33, ST2, Th1 and Th2 cytokines within inflammatory aortic lesions of 18 LVV patients who underwent a surgical




Figure 1. Expression of Th2 and anti-inflammatory cytokines in LVV. (A–C) PBMC of active LVV patients (aLVV) (n = 23) and HD (n = 27) were stimulated for 4 hours with PMA-ionomycin. Expression levels of interleukin 4 (IL-4), interleukin 5 (IL-5) and interleukin 10 (IL-10) measured in supernatant are represented. The levels of IL-4, IL-5 and IL-10 are higher in LVV patients as compared to HD [$p = 0.01$; $p = 0.002$ and $p = 0.003$, respectively]. We used a Mann Whitney test. These data are shown as the mean \pm SEM. (D) Immunofluorescence analysis of inflammatory lesions from LVV patients reveals the expression of Th2 (here IL-4) and IL-10 cytokines partially by CD3 positive cells. Expression of ST2 by Treg (defined as FOXP3 cells) by immunofluorescence analysis. (E) Expression level of IL-33 in LVV (n = 44) patients serum was higher compared to HD (n = 18), * $P < 0.05$. (F) Mean level of soluble ST2 was increased in LVV patient sera (n = 38) as compared to HD (n = 17), *** $P < 0.001$. (G) Level of TSLP in LVV (n = 16) patients serum compared to HD (n = 9). (H) Level of IL-25 in LVV (n = 16) patients serum compared to HD (n = 9).




Figure 2. IL-33 and its receptor ST2 were overexpressed in LVV. **(A)** Immunofluorescence analyses of aorta tissue specimens from LVV patients revealed that IL-33 was mainly expressed within adventitial vessels and co-localized with endothelial cells with positive von willebrand factor (WF) staining. Immunofluorescence analysis of non-inflammatory aorta did not reveal IL-33 positive staining. **(B)** Expression of ST2 was mainly observed within the inflammatory infiltrates in aorta tissue specimen. Immunofluorescence analyses of one non-inflammatory aorta show vessels (WF positive staining) without positive IL-33 staining and absence of ST2 staining. Immunofluorescence analysis of non-inflammatory aorta did not reveal ST2 positive staining. **(C)** The proportion of vessels with positive IL-33 staining was higher in aorta from LVV patients ($n = 5$) as compared to non-inflammatory controls ($n = 3$), $*P < 0.05$. These data are shown as the mean \pm SEM.

repair for an aortic aneurysm/dissection. Relative expression of IL-33 mRNA was significantly correlated with the expression of IL-10 and TGF- β mRNA [$r = 0.6$ ($p = 0.008$) and $r = 0.8$ ($p < 0.0001$), respectively] (Fig. 3D). The relative expression of IL-33 was not correlated with the expression of T-Bet, ROR γ t, GATA3 and IFN γ . The relative expression of ST2 was correlated with those of FOXP3 and GATA-3 [$r = 0.6$ ($p = 0.0035$) and $r = 0.6$ ($p = 0.009$), respectively] (**data not shown**). Altogether, these data suggest a significant correlation between IL33/ST2 axis and regulatory immune response *in vivo*.

To further precise the impact of IL-33 on the immune response within inflammatory lesions, we assessed the secretion of cytokines secreted by GCA temporal arteries ($n = 8$) stimulated or not by IL-33. IL-33 stimulation tended to be associated with increased production of IL-10 by temporal arteries measured by both quantitative determination of cytokines in culture supernatants [$51.4 (\pm 66.1)$ pg/ml vs $18.8 (\pm 12.9)$ pg/ml] and qPCR [relative expression of $1.9 (\pm 1.1)$] from temporal arteries (**data not shown**). IL-33 did not increase the production of IFN γ , nor IL-6 in culture supernatants of temporal arteries (**data not shown**).

Synergic role of IL-33 and stimulated mast cells in immune regulation in LVV. We have previously shown a direct role of IL-33 on T cells polarization. As mast cells (MC) represent one of the main targets of IL-33, we next studied whether MC stimulated by IL-33 could also enhance a regulatory immune response in patients with LVV. First, we demonstrated the presence of MC within inflammatory infiltrates of LVV aorta. Some mast cells in arterial wall had positive staining for IL-33 receptor (ST2/IL-1R4) (Fig. 4A). We have also shown by




Figure 3. IL-33 predominantly induced a Th2 and regulatory immune response in LVV. (A) Freshly isolated PBMC from LVV patients (with corticosteroids <15 mg/day) were cultured with anti-CD3/CD28 with or without IL-33 stimulation for 5 days. The secretion of Th1 and Th2 cytokines was assessed by flow cytometry. Left panel: Dot plots representing IFN γ and IL-4 secreting CD4 $^{+}$ T cells with or without IL-33 stimulation. Right panel: Changes of cytokine production in PBMC stimulated with IL-33 compared to PBMC not stimulated. The proportion of IL-4-secreting CD4 $^{+}$ T cells was increased with IL-33 stimulation ($p=0.01$) in LVV patients ($n=13$) but not in HD ($n=6$). These data are shown as the mean \pm SEM. These results are from 13 independent experiments. (B) After 5 days of culture, quantitative determination of cytokines was performed in culture supernatants ($n=12$) of LVV PBMC. IL-33 stimulation led to a significant increase of IL-5 and IL-4 secretion, * $p<0.05$, *** $p<0.001$. (C) Left panel: Dot plots representing CD25 hi FOXP3 $^{+}$ and CD127 low FOXP3 $^{+}$ CD4 $^{+}$ cells are shown. On the left, PBMC of one LVV patient are cultured for 5 days without IL-33. The frequency of CD127 low FOXP3 $^{+}$ CD4 $^{+}$ cells is shown. On the right, PBMC of the same LVV patient

were cultured for 5 days with IL-33. Right panel: Corresponding results of 15 LVV patients. The frequency of Tregs was increased in stimulated PBMC with IL-33 as compared to those without IL-33. These results are from 4 independent experiments. These data are shown as the mean \pm SEM. $^{**}P < 0.01$. The statistical test used was a Wilcoxon matched pair test. (D) We next assessed by quantitative PCR the expression of IL-33, ST2 and Th1 and Th2 cytokines within LVV aortic lesions ($n = 18$). Relative expression of IL-33 mRNA was significantly correlated with the expression of IL-10 mRNA [$r = 0.6$ ($p = 0.008$)]. Relative expression of IL-33 mRNA was significantly correlated with the expression of TGF- β mRNA [$r = 0.8$ ($p < 0.0001$)].

immunofluorescence an increased number of mast cells in LVV lesions ($n = 7$) within the aorta as compared to non-inflammatory controls [$51.9 (\pm 37.6)$ in LVV vs $3.3 (\pm 3.5)$, $p = 0.02$] (Fig. 4B).

We first assessed the impact of IL-33 on mediators' secretion of MC stimulated with patient serum. In these conditions, there was no impact of IL-33 on IL-4, IL-6, IL-8 and VEGF production (**data not shown**). Next, we have evaluated the impact of IL-33 stimulated- MC on Th2 polarization and on Tregs promotion. CD4 $^{+}$ cells of 8 LVV patients (treated with corticosteroids < 10 mg/day) stimulated with α CD28/ α CD3 were cultured alone or combined with MC with or without IL-33 for 4 days. IL-33-stimulated MC led to a significant increased secretion of IL-5 [$144.7 (\pm 121)$ in CD4 T cells vs $634.8 (\pm 671.5)$ pg/ml in CD4 T cells and MC vs $1168.2 (\pm 1461.5)$ pg/ml in CD4 T cells, MC and IL-33, $p = 0.008$], IL-13 [$1895.4 (\pm 1296.6)$ pg/ml in CD4 T cells vs $4643.2 (\pm 3375.5)$ pg/ml in CD4 T cells and MC vs $9800 (\pm 9548.4)$ pg/ml in CD4 T cells, MC and IL-33, $p = 0.008$ and 0.03] and IL-4 [$74.6 (\pm 79.9)$ pg/ml in CD4 T cells vs $291.5 (\pm 410.1)$ pg/ml in CD4 T cells and MC vs $499.5 (\pm 585.9)$ pg/ml in CD4 T cells, MC and IL-33, $p = 0.03$] (Fig. 4C).

The proportion of Tregs was also determined in each previously described condition. We observed an increase in Treg number when stimulated CD4 $^{+}$ cells of LVV patients were cultured with MC as compared to the condition without MC. The addition of IL-33 to MC further increased the proportion of Treg as compared to the other conditions [median proportion of CD25 hi FOXP3 $^{+}$ CD4 $^{+}$ T cells of 1.88 (0.34; 8.85) % in CD4 $^{+}$ T cells alone vs 5.57 (2.38; 7.79) % in CD4 $^{+}$ T cells plus MC and 11.02 (1.7; 14.84) % in CD4 $^{+}$ T cells plus MC with IL-33 ($p = 0.02$ and 0.008 , respectively)]. Altogether, these results show that MC and IL-33 enhance a regulatory immune response (Figs. 4D and S7).

Finally, we studied by which mechanisms MC stimulated by IL-33 could enhance regulatory response. Quantitative determination of cytokines was also performed in coculture supernatants of MC and CD4 $^{+}$ T cells ($n = 8$). IL-33-stimulated MC led to a significant increase of IL-2 secretion [$136.4 (\pm 167.4)$ pg/ml in CD4 T cells alone vs $2080 (\pm 2808.9)$ pg/ml in CD4 T cells with MC vs $3555.4 (\pm 5062)$ pg/ml in CD4 T cells, MC and IL-33, $p = 0.008$ and 0.03], which may explain the increase of Tregs by MC and IL-33 (Fig. 4D). IL-2 blocking led to a decrease in Treg frequency of 29% ($n = 4$).

IL-33 led to very discreet increase of degranulation by MC (Fig. 4E). However, we found an increased activity of indoleamine 2,3-dioxygenase (IDO) in MC incubated with LVV serum and IL-33 as compared to those not stimulated with IL-33 [$9 (6.7; 15.4)$ % vs $5.8 (2.4; 10.8)$ %, $p = 0.001$]. The increased production of IDO, an important immunomodulatory mediator, also may explain the increase of Treg (Fig. 4E).

Together, the results indicate that IL-33 and MC further enhanced Th2 and regulatory responses by inducing a 6.1 fold increased proportion of Tregs ($p = 0.008$). Stimulation of MC by IL-33 increased indoleamine 2,3-dioxygenase (IDO) activity and IL-33 was associated with an increase in IL-2 secretion (by T cells and/or MC) which participates to production of Tregs.

Discussion

The present study examined the critical role of IL-33 in regulating T cell activation in LVV. IL-33 has been previously found overexpressed of IL-33 in temporal arteries of GCA patients⁶. A meta-analysis has found an association of GCA and an IL-33 genetic variant⁷. However, the functional role of IL-33 in LVV patients is unknown. IL-33 is a key regulator of immune responses shown to license innate and adaptive immunity^{18,19}.

Herein, we found overexpression of IL-33 and its receptor soluble ST2 in LVV patients. Endothelial cells were the main source of IL-33 in inflamed aorta. The analysis of cytokine production in LVV patients pointed out, besides Th1 and Th17 polarization, a secretion of Th2 cytokines increased in LVV patients compared to healthy controls. In addition, IL-4 and IL-10 were expressed within the inflammatory aorta of LVV patients. In hematopoietic cells, IL-33 is known to act primarily on immune cells associated with type 2 response^{8,20}. Through ST2/IL-1R4 interactions, IL-33 induces helper T cells, mast cells and eosinophils to produce type 2 cytokines. Indeed, Th2 cells express constitutively high levels of ST2/IL-1R4. In Th2 GATA3 $^{+}$ cells, combined IL-33 and IL-2/STAT5 increase the expression of GATA-3 and hence promote Th2 program and enhance also the expression of ST2/IL-1R4¹⁸. IL-33 significantly modulates the immune response in favor of type 2 cytokine in LVV. They exert a synergistic effect on IL-5, IL-4 and IL-13 production in LVV patients whereas no significant change was observed for Th1 and Th17 cytokines. In addition, ST2 expression in inflamed aorta was correlated with GATA-3 and FOXP3. These findings are in line with data showing expression of ST2 by Th2 cells and Tregs¹⁸. IL-33 has been shown to exert protective effects in atherosclerosis mice through a switch from a pro-atherosclerotic Th1 type to a protective Th2 type immune response.¹¹ In cardiovascular disease models, IL-33 induction following vascular and cardiac stress was correlated with improved outcomes^{3,11,12,15,27}. Taken together, IL-33 may tilt the Th1 and Th17 inflammatory responses observed in LVV patients.

Since Tregs expressed ST2/IL-1R4 in vessels of LVV, we next studied the impact of IL-33 on Tregs. We have shown that IL-33 expanded functional Tregs. Within inflammatory aorta lesions in LVV patients, the expression of IL-33 mRNA was correlated with those of TGF- β and IL-10 mRNA. Consistently, the addition of human rIL-33 to GCA temporal arteries was associated with an overexpression of IL-10. Besides Th2 polarization, IL-33 acts




Figure 4. IL-33 enhanced a regulatory and Th2 immune response through MC. **(A)** Immunofluorescence staining of LVV inflammatory lesions of 2 LVV patients and 1 non-inflammatory aorta control for ST2 and MC. **(B)** The number of MC within aorta was higher in LVV patients ($n = 7$) than in non-inflammatory controls ($n = 3$) $*P < 0.05$. These data are shown as the mean \pm SEM. **(C)** Quantitative determination of Th2 cytokines in culture supernatants ($n = 8$) of MC and CD4⁺ T cells. IL-33-stimulated MC led to a significant increase in IL-5, IL-13 and IL-4 secretion. $*P < 0.05$, $**P < 0.01$. These data are shown as the mean \pm SEM. **(D)** Left panel: Dot plots representing the proportion of CD25^{high}FOXP3⁺ and CD127^{low}FOXP3⁺ CD4⁺ cells are shown. On the left: CD4⁺ T cells of one LVV patient are cultured for 5 days without IL-33. The proportion of CD127^{low}FOXP3⁺ CD4⁺ cells is shown. On the middle: MC and stimulated CD4 T cells were cultured for 5 days without IL-33. On the right: MC and stimulated T CD4 cells were cultured for 5 days with IL-33. This patient is representative of the whole cohort ($n = 8$). Middle panel: The corresponding results of 8 LVV patients. MC alone and IL-33-stimulated MC promote the increase of Tregs frequency. $*P < 0.05$, $**P < 0.01$. These results are from 8

independent experiments. These data are shown as the mean \pm SEM. Right panel: Quantitative determination of cytokines was performed in culture supernatants ($n = 8$). IL-33-stimulated MC led to a significant increase in IL-2 secretion. $*P < 0.05$, $**P < 0.01$. These data are shown as the mean \pm SEM. (E) Left and middle panels: MC were incubated with LVV serum ($n = 11$) with or without IL-33 stimulation. IL-33 led to a discreet increase of MC degranulation (histamine and tryptase). Right panel: Indoleamine 2,3-dioxygenase (IDO) activity was dramatically increased in MC incubated with IL-33 as compared to those not stimulated with IL-33. $**P < 0.01$, $***P < 0.001$. These data are shown as the mean \pm SEM.

primarily on regulatory immune responses, through mast cells and Tregs^{8,21}. Some Tregs express constitutively high levels of ST2/IL-1R4, IL-33 enhances FOXP3 expression and thereby Tregs program and also boosts the expression of ST2¹⁸. Tissue Tregs are highly suppressive and express IL-10. In inflammatory bowel diseases, ST2/IL-1R4 is preferentially expressed on colonic Tregs cells²² and IL-33 through ST2 promotes Treg function and adaptation to the inflammatory environment. IL-33 signalling enhances TGF β -mediated differentiation, accumulation and maintenance of Treg in inflamed tissue. Altogether, our data suggest a regulatory mechanism of the IL-33/Th2 axis that controls the Th1 and Th17 mediated inflammation. Consistent with the immunomodulatory role of IL-33 in LVV, IL-33 expression was observed at diagnosis in arteries during the acute phase of inflammation. However, we cannot exclude that IL-33 production also characterizes a “healing” stage of vasculitis occurring after the acute phase of inflammation. IL-33 reflects the plasticity of immune cells that secrete cytokines participating in immune regulation and tissue healing, according to the phase of inflammation.

IL-33 and mast cells synergize the expansion of Tregs. Indeed, we showed that IL33 increases Tregs and that this effect is amplified by MC [about 6-fold increase with MC stimulated with IL-33 compared to CD4⁺ T cells alone]. Higher levels of IDO and of IL-2 were observed after stimulation of IL-33 stimulated mast cells. These two molecules are critical in the homeostasis of Tregs²³ and may be key mediators of Tregs expansion. Although mast cells are known to contribute to inflammation in many conditions such as allergy or rheumatoid arthritis²⁴, other reports suggest that they are also critical in enhancing a regulatory immune response^{25–27}. Consistently, MC were found to be central for skin allograft tolerance in mice, via Treg-secreted IL-9 which leads to activation and recruitment of MC²⁵. Rodrigues *et al.* recently found that dendritic cells with direct contact with MC expressed higher levels of PDL1, secreted higher levels of IDO and stimulated regulatory T lymphocytes producing IL-10 and TGF- β ²⁶. In a model of papain-induced allergy, MC stimulated with IL-33 have been shown to be crucial to suppress papain-induced inflammation by promoting regulatory T cells²⁸. IL-33 was shown to both enhance airway eosinophilia and inflammation through ILC2 stimulation but also to lead to increased Treg number through MC and IL-2²⁸. Thus, our results highlight immunomodulatory properties of mast cells in LVV, and suggest that mast cells might be a potential therapeutic target.

In conclusion, our results demonstrate an unrecognized link between an endogenous mediator of tissue damage and an anti-inflammatory pathway in LVV. We provide evidence that IL-33 may regulate inflammation in LVV through their action on Th2 and Tregs cells.

Received: 10 October 2019; Accepted: 25 February 2020;

Published online: 14 April 2020

References

- Watanabe, R., Zhang, H., Berry, G., Goronzy, J. J. & Weyand, C. M. Immune checkpoint dysfunction in large and medium vessel vasculitis. *Am. J. Physiol. Heart Circ. Physiol.* **312**, H1052–H1059 (2017).
- Saadoun, D. *et al.* Th1 and Th17 cytokines drive Takayasu Arteritis inflammation. *Arthritis Rheumatol. Hoboken NJ*, <https://doi.org/10.1002/art.39037> (2015).
- Deng, J., Younge, B. R., Olshen, R. A., Goronzy, J. J. & Weyand, C. M. Th17 and Th1 T-cell responses in giant cell arteritis. *Circulation* **121**, 906–915 (2010).
- Weyand, C. M. & Goronzy, J. J. Immune mechanisms in medium and large-vessel vasculitis. *Nat. Rev. Rheumatol.* **9**, 731–740 (2013).
- Terrier, B. *et al.* Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. *Arthritis Rheum.* **64**, 2001–2011 (2012).
- Ciccia, F. *et al.* IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. *Ann. Rheum. Dis.* **72**, 258–264 (2013).
- Márquez, A. *et al.* A candidate gene approach identifies an IL33 genetic variant as a novel genetic risk factor for GCA. *PLoS One* **9**, e113476 (2014).
- Cayrol, C. & Girard, J.-P. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. *Curr. Opin. Immunol.* **31**, 31–37 (2014).
- Al, L. J. *et al.* Interleukin-33 prevents the development of autoimmune diabetes in NOD mice. - PubMed - NCBI, <https://www.ncbi.nlm.nih.gov/pubmed/30780005>.
- Takatori, H., Makita, S., Ito, T., Matsuki, A. & Nakajima, H. Regulatory Mechanisms of IL-33-ST2-Mediated Allergic Inflammation. *Front. Immunol.* **9**, 2004 (2018).
- Chen, W.-Y., Tsai, T.-H., Yang, J.-L. & Li, L.-C. Therapeutic Strategies for Targeting IL-33/ST2 Signalling for the Treatment of Inflammatory Diseases. *Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol.* **49**, 349–358 (2018).
- Pavlovic, S. *et al.* IL-33 Prevents MLD-STZ Induction of Diabetes and Attenuate Insulinitis in Prediabetic NOD Mice. *Front. Immunol.* **9**, 2646 (2018).
- Griesenauer, B. & Paczesny, S. The ST2/IL-33 Axis in immune Cells during inflammatory Diseases. *Front. Immunol.* **8** (2017).
- Hunder, G. G. *et al.* The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum.* **33**, 1122–1128 (1990).
- The American College of Rheumatology criteria for the classification of Takayasu arteritis. - PubMed - NCBI, <https://www.ncbi.nlm.nih.gov/pubmed/1975175> (1990).
- Saleh, R. *et al.* A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. *Blood* **124**, 111–120 (2014).
- Maneglier, B. *et al.* Simultaneous measurement of kynurenine and tryptophan in human plasma and supernatants of cultured human cells by HPLC with coulometric detection. *Clin. Chem.* **50**, 2166–2168 (2004).

18. Peine, M., Marek, R. M. & Löhning, M. IL-33 in T Cell Differentiation, Function, and Immune Homeostasis. *Trends Immunol.* **37**, 321–333 (2016).
19. Chan, B. C. L., Lam, C. W. K., Tam, L.-S. & Wong, C. K. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives. *Front. Immunol.* **10**, 364 (2019).
20. Liew, F. Y., Girard, J.-P. & Turnquist, H. R. Interleukin-33 in health and disease. *Nat. Rev. Immunol.* **16**, 676–689 (2016).
21. Liew, F. Y., Pitman, N. I. & McInnes, I. B. Disease-associated functions of IL-33: the new kid in the IL-1 family. *Nat. Rev. Immunol.* **10**, 103–110 (2010).
22. Schiering, C. *et al.* The alarmin IL-33 promotes regulatory T-cell function in the intestine. *Nature* **513**, 564–568 (2014).
23. Orabona, C. & Grohmann, U. Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. *Methods Mol. Biol. Clifton NJ* **677**, 269–280 (2011).
24. Xu, D. *et al.* IL-33 exacerbates antigen-induced arthritis by activating mast cells. *Proc. Natl. Acad. Sci.* **105**, 10913–10918 (2008).
25. Lu, L.-F. *et al.* Mast cells are essential intermediaries in regulatory T-cell tolerance. *Nature* **442**, 997–1002 (2006).
26. Rodrigues, C. P. *et al.* Tolerogenic IDO+ dendritic cells are induced by PD-1-expressing mast cells. *Front. Immunol.* **7** (2016).
27. Leveson-Gower, D. B. *et al.* Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells. *Blood* **122**, 3659–3665 (2013).
28. Morita, H. *et al.* An interleukin-33-mast cell-interleukin-2 axis suppresses papain-induced allergic inflammation by promoting regulatory T cell numbers. *Immunity* **43**, 175–186 (2015).

Acknowledgements

We thank all patients and all physicians involved in the care of the patients. We also thank Fabien Pitoiset, Gaith Wedeh, Sophie Vacher, Ivan Bièche, Thomas Vazquez, Guillaume Churlaud, Michele Barbié, Nathalie Ferry, Cornelia Degbe, Sylvain Porrot, and Valentin Quiniou for their input in conducting experiments. We also thank “la fondation pour la recherche médicale”. We acknowledge the thesis “Régulation immunitaire, angiogenèse et homéostasie tissulaire au cours des vascularites des gros vaisseaux” by Anne-Claire Desbois

Author contributions

Anne-Claire Desbois Design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content Patrice Cacoub Interpreted the data; revised the manuscript for intellectual content Aurélie S. Leroyer Major role in the acquisition of data, interpreted the data Edwige Tellier Major role in the acquisition of data, interpreted the data Marlène Garrido Major role in the acquisition of data, interpreted the data Anna Maciejewski-Duval Major role in the acquisition of data, interpreted the data Cloé Comarmond Major role in the acquisition of data, interpreted the data Stéphane Barete Interpreted the data; revised the manuscript for intellectual content Michel Arock Interpreted the data; revised the manuscript for intellectual content Patrick Bruneval Major role in the acquisition of data, interpreted the data Jean-Marie Launay Major role in the acquisition of data, interpreted the data Pierre Fouret Major role in the acquisition of data, interpreted the data Ulrich Blank Major role in the acquisition of data, interpreted the data Michelle Rosenzweig Interpreted the data; revised the manuscript for intellectual content David Klatzmann Interpreted the data; revised the manuscript for intellectual content Mohamed Jarraya Major role in the acquisition of data, Philippe Cluzel Major role in the acquisition of data, Fabien Koskas Major role in the acquisition of data, Gilles Kaplanski Interpreted the data; revised the manuscript for intellectual content David Saadoun Design and conceptualized study; analyzed the data; drafted the manuscript for intellectual content.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-63042-3>.

Correspondence and requests for materials should be addressed to D.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020